

REFERÊNCIAS BIBLIOGRÁFICAS

1. Greco FA, JD. H. *Cancer of Unknown Primary Site*. . *DeVita, Hellman, and Rosenberg's cancer : principles & practice of oncology*. 11th edition. ed. **Philadelphia: Wolters Kluwer**; 2019. p. 1720-37.
2. Losa F, Soler G, Casado A, Estival A, Fernandez I, Gimenez S, et al. *SEOM clinical guideline on unknown primary cancer (2017)*. **Clin Transl Oncol**. 2018;20(1):89-96.
3. Siegel RL, Miller KD, Jemal A. *Cancer statistics, 2019*. **CA Cancer J Clin**. 2019;69(1):7-34.
4. Birendra R, Kekre NS. *Re: A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder Cancer: J. C. Park, N. M. Gandhi, M. A. Carducci, M. A. Eisenberger, A. S. Baras, G. J. Netto, J. J. Liu, C. G. Drake, M. P. Schoenberg, T. J. Bivalacqua and N. M. Hahn J Urol 2016;195:880-885*. **J Urol**. 2016.
5. Pavlidis N. *Cancer of unknown primary: biological and clinical characteristics*. **Ann Oncol**. 2003;14 Suppl 3:iii11-8.
6. Chorost MI, Lee MC, Yeoh CB, Molina M, Ghosh BC. *Unknown primary*. **J Surg Oncol**. 2004;87(4):191-203.
7. Bugat R, Bataillard A, Lesimple T, Voigt JJ, Culine S, Lortholary A, et al. *Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002)*. **Br J Cancer**. 2003;89 Suppl 1:S59-66.
8. Blaszyk H, Hartmann A, Bjornsson J. *Cancer of unknown primary: clinicopathologic correlations*. **APMIS**. 2003;111(12):1089-94.
9. Culine S. *Prognostic factors in unknown primary cancer*. **Semin Oncol**. 2009;36(1):60-4.
10. Hainsworth JD, Fizazi K. *Treatment for patients with unknown primary cancer and favorable prognostic factors*. **Semin Oncol**. 2009;36(1):44-51.
11. Oien KA. *Pathologic evaluation of unknown primary cancer*. **Semin Oncol**. 2009;36(1):8-37.
12. Wick MR. *Immunohistochemical approaches to the diagnosis of undifferentiated malignant tumors*. **Ann Diagn Pathol**. 2008;12(1):72-84.
13. Monzon FA, Koen TJ. *Diagnosis of metastatic neoplasms: molecular approaches for identification of tissue of origin*. **Arch Pathol Lab Med**. 2010;134(2):216-24.

14. Bender RA, Erlander MG. *Molecular classification of unknown primary cancer*. **Semin Oncol**. 2009;36(1):38-43.
15. Kandalaft PL, Gown AM. *Practical Applications in Immunohistochemistry: Carcinomas of Unknown Primary Site*. **Arch Pathol Lab Med**. 2016;140(6):508-23.
16. Dabbs DJ. *Diagnostic Immunohistochemistry E-Book: Theranostic and Genomic Applications*: Elsevier Health Sciences; 2017.
17. Handorf CR, Kulkarni A, Grenert JP, Weiss LM, Rogers WM, Kim OS, et al. *A multicenter study directly comparing the diagnostic accuracy of gene expression profiling and immunohistochemistry for primary site identification in metastatic tumors*. **Am J Surg Pathol**. 2013;37(7):1067-75.
18. Conner JR, Hornick JL. *Metastatic carcinoma of unknown primary: diagnostic approach using immunohistochemistry*. **Adv Anat Pathol**. 2015;22(3):149-67.
19. van de Wouw AJ, Jansen RL, Speel EJ, Hillen HF. *The unknown biology of the unknown primary tumour: a literature review*. **Ann Oncol**. 2003;14(2):191-6.
20. Kamposioras K, Pentheroudakis G, Pavlidis N. *Exploring the biology of cancer of unknown primary: breakthroughs and drawbacks*. **Eur J Clin Invest**. 2013;43(5):491-500.
21. Monzon FA, Dumur CI. *Diagnosis of uncertain primary tumors with the Pathwork tissue-of-origin test*. **Expert Rev Mol Diagn**. 2010;10(1):17-25.
22. Meiri E, Mueller WC, Rosenwald S, Zepeniuk M, Klinke E, Edmonston TB, et al. *A second-generation microRNA-based assay for diagnosing tumor tissue origin*. **Oncologist**. 2012;17(6):801-12.
23. Ferracin M, Pedriali M, Veronese A, Zagatti B, Gafa R, Magri E, et al. *MicroRNA profiling for the identification of cancers with unknown primary tissue-of-origin*. **J Pathol**. 2011;225(1):43-53.
24. Sokilde R, Vincent M, Moller AK, Hansen A, Hoiby PE, Blondal T, et al. *Efficient identification of miRNAs for classification of tumor origin*. **J Mol Diagn**. 2014;16(1):106-15.
25. Santos MTD, Souza BF, Carcano FM, Vidal RO, Scapulatempo-Neto C, Viana CR, et al. *An integrated tool for determining the primary origin site of metastatic tumours*. **J Clin Pathol**. 2018;71(7):584-93.

26. Hainsworth JD, Greco FA. *Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.* **Virchows Arch.** 2014;464(4):393-402.
27. Ross JS, Wang K, Gay L, Otto GA, White E, Iwanik K, et al. *Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.* **JAMA Oncol.** 2015;1(1):40-9.
28. Gatalica Z, Millis SZ, Vranic S, Bender R, Basu GD, Voss A, et al. *Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: analysis of 1806 cases.* **Oncotarget.** 2014;5(23):12440-7.
29. Hainsworth JD, Rubin MS, Spigel DR, Boccia RV, Raby S, Quinn R, et al. *Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.* **J Clin Oncol.** 2013;31(2):217-23.
30. Kim KW, Krajewski KM, Jagannathan JP, Nishino M, Shinagare AB, Hornick JL, et al. *Cancer of unknown primary sites: what radiologists need to know and what oncologists want to know.* **AJR Am J Roentgenol.** 2013;200(3):484-92.
31. Chen K, Chen X. *Positron emission tomography imaging of cancer biology: current status and future prospects.* **Semin Oncol.** 2011;38(1):70-86.
32. Demir H, Berk F, Raderer M, Plowman PN, Lassen U, Daugaard G, et al. *The role of nuclear medicine in the diagnosis of cancer of unknown origin.* **Q J Nucl Med Mol Imaging.** 2004;48(2):164-73.
33. Seve P, Billotey C, Broussolle C, Dumontet C, Mackey JR. *The role of 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site.* **Cancer.** 2007;109(2):292-9.
34. Delgado-Bolton RC, Fernandez-Perez C, Gonzalez-Mate A, Carreras JL. *Meta-analysis of the performance of 18F-FDG PET in primary tumor detection in unknown primary tumors.* **J Nucl Med.** 2003;44(8):1301-14.
35. Townsend DW, Carney JP, Yap JT, Hall NC. *PET/CT today and tomorrow.* **J Nucl Med.** 2004;45 Suppl 1:4S-14S.
36. Bleicher RJ, Morrow M. *MRI and breast cancer: role in detection, diagnosis, and staging.* **Oncology (Williston Park).** 2007;21(12):1521-8, 30; discussion 30, 32-3.

37. Pentheroudakis G, Stoyianni A, Pavlidis N. *Cancer of unknown primary patients with midline nodal distribution: midway between poor and favourable prognosis?* **Cancer Treat Rev.** 2011;37(2):120-6.
38. Goff BA, Mandel L, Muntz HG, Melancon CH. *Ovarian carcinoma diagnosis.* **Cancer.** 2000;89(10):2068-75.
39. Katagiri H, Takahashi M, Inagaki J, Sugiura H, Ito S, Iwata H. *Determining the site of the primary cancer in patients with skeletal metastasis of unknown origin: a retrospective study.* **Cancer.** 1999;86(3):533-7.
40. Varadhachary GR, Abbruzzese JL, Lenzi R. *Diagnostic strategies for unknown primary cancer.* **Cancer.** 2004;100(9):1776-85.
41. Swaid F, Downs D, Rosemurgy AS. *A practical approach to liver metastasis from unknown primary cancer: What surgeons need to know.* **Cancer Genet.** 2016;209(12):559-66.
42. Saliminejad M, Bemanian S, Ho A, Spiegel B, Laine L. *The yield and cost of colonoscopy in patients with metastatic cancer of unknown primary.* **Aliment Pharmacol Ther.** 2013;38(6):628-33.
43. Hyphantis T, Papadimitriou I, Petrakis D, Fountzilias G, Repana D, Assimakopoulos K, et al. *Psychiatric manifestations, personality traits and health-related quality of life in cancer of unknown primary site.* **Psychooncology.** 2013;22(9):2009-15.
44. Kaasa S, Loge JH, Aapro M, Albrecht T, Anderson R, Bruera E, et al. *Integration of oncology and palliative care: a Lancet Oncology Commission.* **Lancet Oncol.** 2018;19(11):e588-e653.
45. Amela EY, Lauridant-Philippin G, Cousin S, Ryckewaert T, Adenis A, Penel N. *Management of "unfavourable" carcinoma of unknown primary site: synthesis of recent literature.* **Crit Rev Oncol Hematol.** 2012;84(2):213-23.
46. Lee J, Hahn S, Kim DW, Kim J, Kang SN, Rha SY, et al. *Evaluation of survival benefits by platinum and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis.* **Br J Cancer.** 2013;108(1):39-48.
47. Hainsworth JD, Johnson DH, Greco FA. *Cisplatin-based combination chemotherapy in the treatment of poorly differentiated carcinoma and poorly differentiated adenocarcinoma of unknown primary site: results of a 12-year experience.* **J Clin Oncol.** 1992;10(6):912-22.
48. van der Gaast A, Verweij J, Henzen-Logmans SC, Rodenburg CJ, Stoter G. *Carcinoma of unknown primary: identification of a treatable subset?* **Ann Oncol.** 1990;1(2):119-22.

49. Huebner G, Link H, Kohne CH, Stahl M, Kretzschmar A, Steinbach S, et al. *Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trial.* **Br J Cancer.** 2009;100(1):44-9.
50. Jeremic B, Zivic DJ, Matovic M, Marinkovic J. *Cisplatin and 5-fluorouracil as induction chemotherapy followed by radiation therapy in metastatic squamous cell carcinoma of an unknown primary tumor localized to the neck. A phase II study.* **J Chemother.** 1993;5(4):262-5.
51. Janssen S, Glanzmann C, Huber G, Studer G. *Individualized IMRT treatment approach for cervical lymph node metastases of unknown primary.* **Strahlenther Onkol.** 2014;190(4):386-93.
52. Hanahan D, Weinberg RA. *Hallmarks of cancer: the next generation.* **Cell.** 2011;144(5):646-74.
53. Spranger S, Gajewski TF. *Mechanisms of Tumor Cell–Intrinsic Immune Evasion.* 2018;2(1):213-28.
54. Cerezo-Wallis D, Soengas M. *Understanding Tumor-Antigen Presentation in the New Era of Cancer Immunotherapy.* **Curr Pharm Des.** 2016.
55. Sharpe AH, Freeman GJ. *The B7-CD28 superfamily.* **Nat Rev Immunol.** 2002;2(2):116-26.
56. Morales A, Eiding D, Bruce AW. *Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.* **J Urol.** 1976;116(2):180-3.
57. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. *Sipuleucel-T immunotherapy for castration-resistant prostate cancer.* **N Engl J Med.** 2010;363(5):411-22.
58. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. *Improved survival with ipilimumab in patients with metastatic melanoma.* **N Engl J Med.** 2010;363(8):711-23.
59. Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, et al. *Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target.* **Proc Natl Acad Sci U S A.** 2004;101(49):17174-9.
60. Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, et al. *Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.* **Proc Natl Acad Sci U S A.** 2007;104(9):3360-5.

61. Ishida Y, Agata Y, Shibahara K, Honjo T. *Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.* **EMBO J.** 1992;11(11):3887-95.
62. Blank C, Mackensen A. *Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion.* **Cancer Immunol Immunother.** 2007;56(5):739-45.
63. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. *Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.* **J Exp Med.** 2000;192(7):1027-34.
64. Topalian SL, Drake CG, Pardoll DM. *Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.* **Curr Opin Immunol.** 2012;24(2):207-12.
65. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. *Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade.* **Proc Natl Acad Sci U S A.** 2002;99(19):12293-7.
66. Leventakos K, Mansfield AS. *Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab.* **BioDrugs.** 2016.
67. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. *Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.* **J Clin Oncol.** 2010;28(19):3167-75.
68. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. *Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.* **N Engl J Med.** 2012;366(26):2443-54.
69. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. *Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.* **N Engl J Med.** 2012;366(26):2455-65.
70. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. *Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.* **Nature.** 2014;515(7528):563-7.
71. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. *Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.* **Lancet.** 2014;384(9948):1109-17.
72. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. *Pembrolizumab versus Ipilimumab in Advanced Melanoma.* **N Engl J Med.** 2015;372(26):2521-32.

73. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, et al. *Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.* **Lancet Oncol.** 2015;16(4):375-84.
74. Balar AV, Weber JS. *PD-1 and PD-L1 antibodies in cancer: current status and future directions.* **Cancer Immunol Immunother.** 2017;66(5):551-64.
75. Dijkstra KK, Voabil P, Schumacher TN, Voest EE. *Genomics- and Transcriptomics-Based Patient Selection for Cancer Treatment With Immune Checkpoint Inhibitors: A Review.* **JAMA Oncol.** 2016;2(11):1490-5.
76. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. *Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study.* **Lancet Oncol.** 2017;18(9):1182-91.
77. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. *Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.* **J Biomed Inform.** 2009;42(2):377-81.
78. Roach C, Zhang N, Corigliano E, Jansson M, Toland G, Ponto G, et al. *Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer.* **Appl Immunohistochem Mol Morphol.** 2016;24(6):392-7.
79. Kulangara K, Zhang N, Corigliano E, Guerrero L, Waldroup S, Jaiswal D, et al. *Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer.* **Arch Pathol Lab Med.** 2019;143(3):330-7.
80. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. *Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.* **N Engl J Med.** 2015;373(19):1803-13.
81. Golfinopoulos V, Pentheroudakis G, Salanti G, Nearchou AD, Ioannidis JP, Pavlidis N. *Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis.* **Cancer Treat Rev.** 2009;35(7):570-3.
82. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. *Diagnostic and therapeutic management of cancer of an unknown primary.* **Eur J Cancer.** 2003;39(14):1990-2005.
83. Greco FA, Pavlidis N. *Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors.* **Semin Oncol.** 2009;36(1):65-74.

84. Kim CS, Hannouf MB, Sarma S, Rodrigues GB, Rogan PK, Mahmud SM, et al. *Survival outcome differences based on treatments used and knowledge of the primary tumour site for patients with cancer of unknown and known primary in Ontario.* **Curr Oncol.** 2018;25(5):307-16.
85. Wen Y, Chen Y, Duan X, Zhu W, Cai C, Deng T, et al. *The clinicopathological and prognostic value of PD-L1 in urothelial carcinoma: a meta-analysis.* **Clin Exp Med.** 2019;19(4):407-16.
86. Zhou ZJ, Zhan P, Song Y. *PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis.* **Transl Lung Cancer Res.** 2015;4(2):203-8.
87. Gajewski TF, Schreiber H, Fu YX. *Innate and adaptive immune cells in the tumor microenvironment.* **Nat Immunol.** 2013;14(10):1014-22.
88. Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Lubner BS, Wang H, et al. *PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival.* **Cancer Immunol Res.** 2013;1(1):54-63.
89. Huang W, Ran R, Shao B, Li H. *Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis.* **Breast Cancer Res Treat.** 2019;178(1):17-33.
90. Daassi D, Mahoney KM, Freeman GJ. *The importance of exosomal PDL1 in tumour immune evasion.* **Nat Rev Immunol.** 2020;20(4):209-15.
91. Pyo JS, Kang G, Kim JY. *Prognostic role of PD-L1 in malignant solid tumors: a meta-analysis.* **Int J Biol Markers.** 2017;32(1):e68-e74.
92. Koomen BM, Badrising SK, van den Heuvel MM, Willems SM. *Comparability of PD-L1 immunohistochemistry assays for non-small-cell lung cancer: a systematic review.* **Histopathology.** 2020;76(6):793-802.
93. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. *Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.* **N Engl J Med.** 2015;373(1):23-34.
94. Chen J, Jiang CC, Jin L, Zhang XD. *Regulation of PD-L1: a novel role of pro-survival signalling in cancer.* **Ann Oncol.** 2016;27(3):409-16.
95. Mansfield AS, Murphy SJ, Peikert T, Yi ES, Vasmatazis G, Wigle DA, et al. *Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer.* 2016;22(9):2177-82.

96. Patel SP, Kurzrock R. *PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy*. **Mol Cancer Ther**. 2015;14(4):847-56.
97. Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba, II, Hirsch FR, et al. *Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art?* **J Thorac Oncol**. 2015;10(7):985-9.
98. Khunger M, Hernandez AV, Pasupuleti V, Rakshit S, Pennell NA, Stevenson J, et al. *Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis*. 2017(1):1-15.
99. Garon EB, Rizvi NA, Hui R, Leigh N, Balmanoukian AS, Eder JP, et al. *Pembrolizumab for the treatment of non-small-cell lung cancer*. **N Engl J Med**. 2015;372(21):2018-28.
100. Hainsworth JD, Greco FA. *Cancer of Unknown Primary Site: New Treatment Paradigms in the Era of Precision Medicine*. **Am Soc Clin Oncol Educ Book**. 2018;38:20-5.
101. Gatalica Z, Xiu J, Swensen J, Vranic S. *Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy*. **Eur J Cancer**. 2018;94:179-86.
102. Haratani K, Hayashi H, Takahama T, Nakamura Y, Tomida S, Yoshida T, et al. *Clinical and immune profiling for cancer of unknown primary site*. **J Immunother Cancer**. 2019;7(1):251.
103. Ribas A, Wolchok JD. *Cancer immunotherapy using checkpoint blockade*. **Science**. 2018;359(6382):1350-5.
104. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, et al. *Phase 2 study of pembrolizumab in patients with advanced rare cancers*. **J Immunother Cancer**. 2020;8(1).
105. Tanizaki J, Yonemori K, Akiyoshi K, Minami H, Ueda H, Takiguchi Y, et al. *NivoCUP: An open-label phase II study on the efficacy of nivolumab in cancer of unknown primary*. 2020;38(15_suppl):106-.